Navigation Links
Hong Kong Cancer Center First in Asia to Commence Treating Cancer Patients Using TrueBeam™ System for Image-Guided Radiotherapy
Date:11/2/2011

HONG KONG, Nov. 2, 2011 /PRNewswire/ -- The Hong Kong Sanatorium & Hospital here has become the first clinic in Asia to commence treating cancer using the TrueBeam™ system from Varian Medical Systems (NYSE: VAR).  Clinicians used the new system on September 28, for the palliative treatment of a metastatic bone lesion, and then again on October 6, to deliver an image-guided and intensity-modulated radiotherapy treatment for a patient battling head and neck cancer.

"The TrueBeam system improves on earlier generations of technology," said Dr. Wing-Hong Kwan, MD, Director of the Department of Radiotherapy at the Hong Kong Sanatorium & Hospital.  "It offers excellent 3-D imaging capabilities so that we can target the tumor with great accuracy.  Using this system, we will be able to quickly deliver high doses to the tumor while limiting exposure of the surrounding tissues and organs."

According to Dr. Kwan, two special capabilities of the TrueBeam system stand out as particularly exciting: the ability to synchronize treatment with a patient's respiratory motion, and the ability to generate real-time images during treatment.  "These capabilities enable us to verify and confirm that we are accurately targeting the tumor throughout a course of treatment," he said.  "They provide us with an added measure of accuracy."

About the TrueBeam SystemTrueBeam was designed to treat tumors with increased speed and accuracy, including tumors that move during treatment as the patient breathes.  It features several technical innovations that dynamically synchronize and integrate imaging, patient positioning, motion management, and treatment delivery during sophisticated treatments for cancer.  With its High Intensity Mode, TrueBeam can accurately deliver high doses, more than twice as fast as earlier generations of technology.  This makes it possible to significantly shorten treatments, potentially enabling clinics to treat more patients each day and to improve precision by leaving less time for tumor motion during dose delivery.

"The TrueBeam system is Varian's most advanced offering for dealing with tumor motion, which makes it especially well-suited for treating cancer of the lung and liver, two types that occur commonly in Asia," said Tom Duffy, head of Varian's Oncology Systems business in Asia. "We are honored to work with the Hong Kong Sanatorium & Hospital, which is very much on the leading edge of cancer care, having adopted this modern technology for the benefit of cancer patients in Hong Kong."

TrueBeam was approved for sale in China by the Chinese State Food and Drug Administration (SFDA) earlier this year.

About Hong Kong Sanatorium & HospitalHong Kong Sanatorium & Hospital is one of the leading private hospitals in Hong Kong. With the motto "Quality in Service Excellence in Care", the Hospital is committed to serving the public as well as promoting medical education and research.

About Varian Medical SystemsVarian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,700 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. The company's center in Beijing encompasses oncology equipment manufacturing operations, an educational center for radiotherapy clinical professionals, a customer service center, and X-ray Products assembly and service. For more information, visit http://www.varian.com.FOR INFORMATION CONTACT:  UNITED STATES

ASIAMeryl Ginsberg

Alan TangTel: 1.650.424.6444

Tel: + 852 2369 4280Cell: 1. 650.996.7487

Cell: + 852 9283 2429meryl.ginsberg@varian.com

AlanCY.Tang@varian.com
'/>"/>

SOURCE Varian Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... 14, 2017 The Bio Supply Management Alliance ... of Fremont and the Biomedical Manufacturing Network ... in California by providing a ... and fostering workforce development. The primary focus of this ... start-ups, as well as small and mid-sized biomedical companies. ...
(Date:6/11/2017)... 2017  Eli Lilly and Company (NYSE: LLY ... studies of galcanezumab, an investigational treatment for the prevention ... several key secondary endpoints for galcanezumab compared to placebo ... (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented today at ... Boston . "The ...
(Date:6/8/2017)... MAITLAND, Fla. , June 8, 2017  Less ... ransomware attack that hit more than 200,000 companies, including hospital ... is being heralded as one of the largest online ... technology in the healthcare market, it is imperative that ... can protect their data from this — and many ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... June 28, 2017 , ... The parent company of ... employee engagement. Omaha-based C&A Industries, a national leader in staffing and recruitment, ... in North America for 2017. The annual award, issued by Achievers, an ...
(Date:6/28/2017)... ... June 28, 2017 , ... Guide to FDA and ... , No matter on which side of the Atlantic devicemakers do business, this fully ... have to follow. , In addition to the full text of the FDA’s regulations ...
(Date:6/28/2017)... ... June 28, 2017 , ... Eating disorders have the highest ... minutes, at least one person dies as a direct result from an eating disorder ... for qualified treatment providers. The iaedp Foundation meets this challenge by offering what has ...
(Date:6/28/2017)... ... June 28, 2017 , ... American Farmer proudly announces the ... the award winning television series, scheduled to broadcast fourth quarter 2017. American Farmer airs ... a regional supplier of garden pea seed. As demand grew, the small company located ...
(Date:6/28/2017)... ... June 28, 2017 , ... Schneider Insurance and Financial, a ... in southern Montana, is announcing a focused charity effort to gather regional support ... offered by Zoo Montana provide students with current knowledge on the characteristics and ...
Breaking Medicine News(10 mins):